Investigational drug · Phase 3
IBI310
Not approved by FDA. In 2 industry-sponsored Phase 2 or 3 trials that are active or finished in the last two years, most often for Hepatocellular Carcinoma (HCC), Hepatocellular Carcinoma.
Phase 3Last checked: Nov 19, 2026Latest source record: Apr 16, 2026 (newest trial update)Source: ClinicalTrials.govMethods & limitations
Highest phase
Phase 3
Industry-sponsored trials
Phase 2 and 3 trials
2
1 still active
All registered trials
26
Any phase or sponsor naming "IBI310"
First trial start
2021
Feb 7, 2021
Sponsors
Lead sponsors of its Phase 2 and 3 trials.
All registered trials by phase
Every ClinicalTrials.gov drug study naming "IBI310", any sponsor or status.
- Phase 216
Conditions studied
As listed on its trial records.
- Hepatocellular Carcinoma (HCC)
- Hepatocellular Carcinoma
Approved drugs for the same conditions: Liver cancer (hepatocellular carcinoma) · Oncology
Largest trials
Live from ClinicalTrials.gov: studies naming "IBI310" as an intervention, largest first.
- A Study to Evaluate the Efficacy and Safety of IBI310 and Sintilimab Combination Therapy in Patients With Hepatocellular Carcinoma as First-line Treatment.Pivotal-lookingRecruiting
Innovent Biopharmaceutical Technology (Hangzhou) Co., LTD.Industry
NCT07490262 · 680 participants (planned) · Start Mar 27, 2026 · Primary completion Dec 31, 2027
Drug: Bevacizumab; Capecitabine and 3 more · For: Hepatocellular Carcinoma (HCC)
Sites: Hefei, China; Shanghai, China
- Sintilimab Plus Ipilimumab N01 and Chemotherapy Versus Sintilimab Plus Chemotherapy as First-Line Treatment for Advanced Gastric or Gastroesophageal Junction Adenocarcinoma With PD-L1 CPS <5Pivotal-lookingNot yet recruiting
The Affiliated Nanjing Drum Tower Hospital of Nanjing University Medical SchoolAcademic, hospital or other
NCT07942285 · 525 participants (planned) · Start Nov 20, 2026 · Primary completion Dec 31, 2029
Drug: sintilimab+IBI310+chemotherapy; sintilimab+chemotherapy · For: Gastric Adenocarcinoma and Gastroesophageal Junction Adenocarcinoma
Sites: Nanjing, China; Chengdu, China; Tianjin, China
- A Clinical Trial Evaluating the Efficacy and Safety of IBI310 in Combination With Sintilimab, for Neoadjuvant Treatment of MSI-H/dMMR Resectable Colon CancerPivotal-lookingActive, not recruiting
Innovent Biologics (Suzhou) Co. Ltd.Industry
NCT05890742 · 453 participants · Start May 25, 2023 · Primary completion Apr 15, 2028
Drug: Sintilimab; IBI310&Sintilimab · For: MSI-H
Sites: Guangzhou, China
- A Study to Compare the Effectiveness and Safety of IBI310 Combined With Sintilimab Versus Sorafenib in the First-line Treatment of Advanced HCCPivotal-lookingCompleted
Innovent Biologics (Suzhou) Co. Ltd.Industry
NCT04720716 · 344 participants · Start Feb 7, 2021 · Primary completion Dec 31, 2025
Drug: IBI310; Sintilimab and 1 more · For: Hepatocellular Carcinoma
Sites: Shanghai, China
- Efficacy of PD-1 Inhibitor Combination Therapy in Non-small Cell Lung Cancer Patients Who Have Not Achieved Major Pathologic Response After Neoadjuvant Immunotherapy: a Multicenter, Phase II Clinical TrialPivotal-lookingNot yet recruiting
Shanghai Pulmonary Hospital, Shanghai, ChinaAcademic, hospital or other
NCT06620822 · 296 participants (planned) · Start Sep 30, 2024 · Primary completion Sep 30, 2026
Drug: IBI363; LM-108+Sintilimab and 2 more · For: Non Small Cell Lung Cancer
Sites: Shanghai, China
Innovent Biologics (Suzhou) Co. Ltd.Industry
NCT04590599 · 205 participants · Start Dec 8, 2020 · Primary completion Nov 20, 2023
Drug: IBI310; Placebo and 1 more · For: Advanced Cervical Cancer
Sites: Suzhou, China; Zhenjiang, China
- A Study to Evaluate the Similarity in Pharmacokinetics and Safety of IBI310 and Ipilimumab(YERVOY)in Adult Healthy Chinese Male VolunteersPivotal-lookingCompleted
Innovent Biologics (Suzhou) Co. Ltd.Industry
NCT04868760 · 148 participants · Start May 31, 2021 · Primary completion May 2, 2022
Drug: Ipilimumab; IBI310 · For: Healthy Subjects
Sites: Shanghai, China
- The Study of IBI310 in Combination With IBI308 Compared to High-Dose Interferon In Patients With Acral Melanoma That Has Been Removed by SurgeryPivotal-lookingTerminated
Innovent Biologics (Suzhou) Co. Ltd.Industry
NCT04277663 · 136 participants · Start Apr 17, 2020 · Primary completion Feb 28, 2023
Drug: IBI310+IBI308; IBI308 and 1 more · For: Acral Melanoma That Has Been Removed by Surgery
Sites: Beijing, China
Innovent Biologics (Suzhou) Co. Ltd.Industry
NCT04401813 · 97 participants · Start Jun 16, 2020 · Primary completion Jun 21, 2024
Drug: IBI308 200mg · For: Advanced Hepatocellular Carcinoma
Sites: Shanghai, China
Shanghai Zhongshan HospitalAcademic, hospital or other
NCT07714317 · 90 participants (planned) · Start Jul 20, 2026 · Primary completion Jul 31, 2027
Drug: IBI310+ sintilimab + bevacizumab; IBI310+ sintilimab and 1 more · For: Resectable Hepatocellular Carcinoma
Newest research
PubMed records naming it or its code names, newest first.
- Neoadjuvant Immunotherapy in Localized dMMR/MSI-H Colon Cancer: A Systematic Review of Pathological Response and Surgical Outcomes.
Gosavi R, Smith B, Chouhan H, et al. · Ann Surg Oncol 2026
- Surufatinib combined with sintilimab and IBI310 for the treatment of high-grade advanced-neuroendocrine neoplasms: A single arm, open-label, single-center, phase II study.
Zhang P, Zhang M, Wang Y, et al. · Int J Cancer 2026
- Neoadjuvant treatment of IBI310 plus sintilimab in locally advanced MSI-H/dMMR colon cancer: A randomized phase 1b study.
Wang F, Chen G, Qiu M, et al. · Cancer Cell 2025
- Bringing immunotherapy to clinical practice in dMMR/MSI-high colon cancer.
Randon G, Montroni I, Pietrantonio F · Cancer Cell 2025
- IBI310 plus sintilimab vs. placebo plus sintilimab in recurrent/metastatic cervical cancer: A double-blind, randomized controlled trial.
Li H, Xu Y, Jiao X, et al. · Med 2025
- IBI310 (anti-CTLA-4 antibody) monotherapy or in combination with sintilimab in advanced melanoma or urothelial carcinoma.
Cui C, Li J, Yang Y, et al. · Innovation (Camb) 2024
Also in development for Hepatocellular Carcinoma (HCC)
- SintilimabIBI308Phase 321 trials
Innovent Biologics (Suzhou) Co. Ltd. · Hepatocellular Carcinoma, Solid Tumor, HCC - Hepatocellular Carcinoma
- ZanzalintinibXL092Phase 311 trials
Exelixis · Colorectal Cancer, Renal Cell Carcinoma, Head and Neck Squamous Cell Carcinoma
- ApatinibRIVO, RivoceranibPhase 39 trials
Jiangsu HengRui Medicine Co., Ltd. · Gastric Cancer, HCC, Hepatocellular Carcinoma
- CamrelizumabSHR-1210, CAMPhase 39 trials
Jiangsu HengRui Medicine Co., Ltd. · HCC, Non-squamous Non-small Cell Lung Cancer, Hepatocellular Carcinoma
- tinengotinibTT-00420Phase 36 trials
TransThera Sciences (Nanjing), Inc. · Prostate Cancer (CRPC), Cholangiocarcinoma, Hepatocellular Carcinoma (HCC)
- CobolimabPhase 32 trials
GSK · Melanoma, Hodgkin Lymphoma, High and Low Grade Glioma
- TPST-1120Phase 32 trials
Roche (Genentech) · Advanced Liver Cancers, Hepatocellular Carcinoma (HCC)
- HLX13Phase 31 trial
Shanghai Henlius Biotech · Hepatocellular Carcinoma (HCC)
Names are merged from how sponsors list this drug on ClinicalTrials.gov, so an alias can occasionally belong to a related compound. Development status changes faster than registry records do.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.